Bronchus and lung cancer-related mortality trends in the United States from 1999 to 2023 Authors: Mingfeng Wei, Yun Wu, Zheng Li, Xiaoyu Chen, Xuelin Zhang, Fuzhi Yang, Shuai Jiang, Lefei Hu, Shixiang Guo, Xunxia Zhu, Xiaoyong Shen Published: 2026 ABSTRACT AbstractBackgroundBronchus and lung cancer are one of the most common and deadly types of cancer in the United States. This study analyzed the mortality trends related to bronchus and lung cancer among U.S. adults ≥ 25 years old from 1999 to 2023 from demographic and geographic perspectives.MethodsWe utilized the CDC WONDER database to investigate the trends in Bronchus and lung cancer-related mortality in the United States. Age-adjusted mortality rates per 100,000 people (AAMR), annual percentage change (APC), and average annual percentage change (AAPC) with 95% confidence intervals (CIs) were calculated, and the data were stratified by year, age groups, sex, race/ethnicity, census region, urban–rural, and states classification. The Joinpoint Regression Program was utilized to estimate mortality trends between 1999 and 2023.ResultsFrom 1999 to 2023, 3 778 040 bronchus and lung-cancer deaths were recorded. The AAMRs fell from 55.41 per 100 000 (95% CI: 55.14 to 55.69) in 1999 to 29.49 (95% CI: 29.33 to 29.65) in 2023, yielding an average AAPC of -2.63% (95% CI: -2.92 to -2.34; p < 0.001). Crude mortality rates decreased in every age group; The 25–34 age group maintained the lowest CMRs, and decreased modestly (AAPC: -2.515, 95% CI: -3.07 to -1.96). Males exhibited higher AAMRs than females, but their decline was steeper (male AAPC: -3.35%; 95% CI: -3.68 to -3.01 vs female -1.85%; 95% CI: -2.09 to -1.61; both p < 0.001). Non-Hispanic Black individuals had the highest AAMRs consistently but recorded the fastest decrease (AAPC -3.05%; 95% CI: -3.26 to -2.83; p < 0.001), while Hispanic or Latino individuals had the lowest (AAMR 2023: 20.21; 95% CI: 19.67 to 20.75). Geographically, the West had the lowest AAMR and the sharpest decline (AAPC: -3.21%; 95% CI: -3.57 to -2.84; p < 0.001). Metropolitan areas improved faster than non-metropolitan areas (AAPC: -2.83% vs -1.73%; both p < 0.001). By state, the largest 1999 to 2023 reductions were observed in the District of Columbia (-59%), Nevada (-57%), and California (-56%), whereas Kentucky remained the highest in 2023 (AAMR: 75.62; 95% CI: 74.28 to 76.96). A minor rebound in 2020–2023 (APC: -3.02%; 95% CI: -3.79 to -2.24; p = 0.004) coincided with the COVID-19 period.ConclusionIt is crucial to assess potential health disparities among different regions and population groups. There is an urgent need for further research and the implementation of targeted public health interventions, as well as improvements in resource allocation and health outcomes among populations.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13019-026-04075-z.Keywords: CDC WONDER, Bronchus and lung cancer, Mortality trends Introduction Bronchus and lung cancer is one of the most common and deadly types of cancer in the United States. It can invade surrounding tissues and spread to other parts of the body through the bloodstream or lymphatic system [1, 2]. The two main types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with NSCLC being the most prevalent form [3, 4]. It has been well-documented that bronchus and lung cancer are frequently the result of chronic exposure to carcinogens, most notably cigarette smoke, which remains the leading cause of bronchus and lung cancer globally [5]. Sex differences in lung cancer mortality reflect both historical smoking patterns and possible hormonal modulation of tobacco carcinogenesis [6]. Black–White disparities persist after adjustment for smoking, suggesting differential metabolism of nicotine, higher exposure to occupational carcinogens, and unequal access to early detection. Rural populations face elevated radon levels and delayed diagnosis, whereas state-level variation mirrors differences in tobacco control policies [7]. But previous studies have rarely depicted simultaneous urban–rural disparities, and most data series ended in 2020, leaving the COVID-transition period (2021–2023) unexplored. We extend the analysis to 2023 while stratifying by metropolitan status and state [7, 8]. These mechanisms informed our stratification; however, the present study is descriptive and does not test causal pathways. Today, lung-cancer treatments—including surgery, chemotherapy, immunotherapy, targeted therapy, and their combinations—have all achieved favorable outcomes in the general population [9]. Despite therapeutic progress, bronchus and lung cancer continue to pose a substantial health challenge in the United States. It remains the primary cause of cancer-related mortality, with around 235,000 new cases diagnosed and over 125,000 deaths each year [10]. In this study, the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database was examined from 1999 to 2023 to assess concurrent mortality trends of lung cancer in the United States, stratified by age groups, sex, race/ethnicity, census region, and urban–rural, state [11]. This analysis is crucial for developing targeted interventions to mitigate the disease burden. Methods Research context and population To investigate mortality trends related to bronchus and lung cancer, we utilized death certificate data from the CDC WONDER database, covering the period from 1999 to 2023. Diagnostic coding was based on the International Classification of Diseases, 10th Revision (ICD-10) [12], using codes C34.0, C34.1, C34.2, C34.3, C34.8, and C34.9 to identify cases of lung and bronchus cancer. The study focused on Bronchus and Lung Cancer-related deaths among individuals aged more than 25 years in the United States. This age range was selected because lung cancer is uncommon in individuals under 25 years of age, and we aimed to focus on the older population, where the prevalence of this disease is higher [13–15]. CDC WONDER compiles de-identified mortality information from death certificates filed in all 50 states and the District of Columbia; denominator populations are derived from inter-censual bridged-race estimates. The mortality records were derived from U.S. death certificates completed by attending physicians, medical examiners or coroners and filed with state vital-statistics offices. These certificates are compiled and maintained by the National Center for Health Statistics (NCHS) within the CDC and released to researchers through the WONDER online database (https://wonder.cdc.gov). The file is publicly accessible at https://wonder.cdc.gov/ucd-icd10.html and has been used extensively in prior national cancer-mortality analyses [16]. The study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [17]. Data extraction Population size, year, demographics, geographic division, and state-specific data were included. Demographics refer to age, sex (classified as male or female), and race/ethnicity. As seen in similar studies, age groups were defined as 25–34, 35–44, 45–54, 55–64, 65–74, 75–84, and 85+ years of age [18], and race/ethnicity was categorized into Hispanic, Non-Hispanic (NH) Black, NH White, and NH Other groups (including NH Asian or Pacific Islander, NH Hawaiians, NH American Indian or Alaska Native, among others) [19]. For geographic variables: The urban–rural classification was based on the National Center for Health Statistics (NCHS) scheme, which categorizes areas into Metropolitan and nonmetropolitan regions. The former regions include Large Central Metro, Large Fringe Metro, Medium Metro, and Small Metro, while the latter include Micropolitan (Nonmetro) and Noncore (Nonmetro) in the database [20]. Due to missing urban–rural data for 2021–2023, the corresponding stratified analyses for these years were not conducted in this study. States include the District of Columbia, all 50 states, and other states being included. Categorization of geographical areas into the Northeast, Midwest, South, and West regions was done via the United States Census Bureau’s criteria [20]. The data utilized in the analysis was death certificate-reported information and have also been a source for earlier research using the aforementioned database. Statistical analysis To examine national trends in bronchus and lung cancer mortality from 1999 to 2023, we computed both crude and age-adjusted mortality rates (AAMRs) per 100,000 population. These rates were analyzed by age group, sex, race/ethnicity, census region, urban–rural classification, and states, with 95% confidence intervals (CIs) provided. Crude rates were derived by dividing Bronchus and Lung Cancer deaths by the U.S. population for each year. AAMRs were standardized to the 2000 U.S. population [21]. We used the Joinpoint Regression Program (Version 5.0) to calculate annual percentage changes (APCs) and 95% CIs for AAMRs to evaluate annual trends [22]. The weighted average of APCs, reported as average annual percentage changes (AAPCs) with 95% CIs, summarized the overall mortality trend. APCs and AAPCs were considered significant if the slope of mortality change over time was significantly different from zero (p ≤ 0.05) by a two-tailed t-test. As the CDC WONDER database does not provide individual-level covariates, this study could not estimate individual-level adjusted effects and thus employed stratified trend analysis only. All data processing and graphical analyses were conducted using RStudio (version 4.4.3). Results Between 1999 and 2023, there were 3 778 040 Bronchus and Lung Cancer-related deaths in the United States (Table 1). The overall Bronchus and Lung Cancer-related AAMR was 55.41 in 1999, decreasing to 29.49 in 2023 per 1,000,000 individuals, with an average annual percentage change (AAPC) of -2.6268 (Table 2). Initially, there was a non-significant decrease from 1999 to 2002 (APC: -0.26; 95% CI: -1.41 to 0.90). However, this trend changed significantly from 2002 to 2010, with a substantial decline observed during this period (APC: -1.84; 95% CI: -2.15 to -1.54). After 2010, the decline continued, with a significant decrease through 2014 (APC: -3.00; 95% CI: -4.12 to -1.86). This downward trend persisted from 2014 to 2019, with a notable acceleration in the rate of decrease (APC: -4.65; 95% CI: -5.37 to -3.92). Finally, after 2019, there was a significant decrease through 2023 (APC: -3.02; 95% CI: -3.79 to -2.24) (Fig. 1). Table 1Overall bronchus and lung cancer-related deaths adults in the United States, 1999 to 2023CharacteristicDeaths%Age group (years)25–3434950.0935–4438,5271.0245–54244,0406.4655–64742,03719.6465–741,207,57831.9675–841,120,26029.6585 + 422,10311.17SexMale2,091,70055.36Female1,686,34044.64Race/EthnicityHispanic or Latino123,3373.27Non-Hispanic white3,154,26383.67Non-Hispanic Black394,21810.46Non-Hispanic Other98,2142.61Census regionMidwest913,12924.17Northeast689,49318.25South1,526,69740.41West648,72117.17Urban–Rural*Metropolitan2,694,73979.72Nonmetropolitan685,38220.28* Due to missing urban–rural data for 2021–2023, the corresponding stratified analyses for these years were not conducted in this study Overall bronchus and lung cancer-related deaths adults in the United States, 1999 to 2023 * Due to missing urban–rural data for 2021–2023, the corresponding stratified analyses for these years were not conducted in this study Table 2Annual Percentage Changes (APCs) and Average Annual Percentage Changes (AAPCs) in Bronchus and Lung Cancer-related mortality in the United States from 1999 to 2023VariableLower endpoint – Upper endpointAPC (95% CI)P-valueAAPC (95% CI)P-valueOverall1999 – 2002-0.26 ( -1.41 – 0.90)0.629609-2.63 (-2.92 to -2.34) < 0.0000012002 – 2010-1.84 ( -2.15 – -1.54) < 0.0000012010 – 2014-3.00 ( -4.12 – -1.86)0.0001272014 – 2019-4.65 ( -5.37 – -3.92) < 0.0000012019 – 2023-3.02 ( -3.79 – -2.24)0.000004SexMale1999 – 2001-0.93 ( -2.99 – 1.17)0.347079-3.35 (-3.68 to -3.01) < 0.0000012001 – 2010-2.48 ( -2.71 – -2.26) < 0.0000012010 – 2015-3.83 ( -4.48 – -3.16) < 0.0000012015 – 2018-5.62 ( -7.72 – -3.47)0.0001482018 – 2023-3.99 ( -4.50 – -3.48) < 0.000001Female1999 – 20020.98 ( -0.08 – 2.06)0.066034-1.85 (-2.09 to -1.61) < 0.0000012002 – 2008-0.90 ( -1.35 – -0.45)0.0010872008 – 2014-2.09 ( -2.54 – -1.65)0.0000012014 – 2020-4.08 ( -4.52 – -3.63) < 0.0000012020 – 2023-1.52 ( -2.57 – -0.46)0.009454Race/EthnicityHispanic or Latino1999 – 2014-2.12 ( -2.34 – -1.90) < 0.000001-2.73 (-3.30 to -2.16) < 0.0000012014 – 2017-5.59 ( -9.92 – -1.05)0.0194042017 – 2023-2.81 ( -3.57 – -2.04)0.000001NH black1999 – 2004-1.60 ( -2.10 – -1.09)0.00001-3.05 (-3.26 to -2.83) < 0.0000012004 – 2013-2.57 ( -2.82 – -2.33) < 0.0000012013 – 2020-4.95 ( -5.33 – -4.57) < 0.0000012020 – 2023-2.38 ( -3.59 – -1.15)0.001022NH white1999 – 20010.61 ( -1.62 – 2.90)0.562185-2.32 (-2.60 to -2.04) < 0.0000012001 – 2008-1.31 ( -1.68 – -0.94)0.0000092008 – 2014-2.48 ( -2.97 – -1.98) < 0.0000012014 – 2019-4.41 ( -5.13 – -3.69) < 0.0000012019 – 2023-2.66 ( -3.43 – -1.88)0.000013NH other1999 – 2011-0.83 ( -1.15 – -0.51)0.000029-2.16 (-2.35 to -1.97) < 0.0000012011 – 2023-3.46 ( -3.71 – -3.22) < 0.000001Census regionMidwest1999 – 20020.18 ( -1.12 – 1.49)0.772914-2.09 (-2.40 to -1.79) < 0.0000012002 – 2008-1.10 ( -1.66 – -0.53)0.001432008 – 2014-2.06 ( -2.63 – -1.49)0.0000072014 – 2019-4.34 ( -5.15 – -3.53) < 0.0000012019 – 2023-2.46 ( -3.32 – -1.58)0.000073Northeast1999 – 2002-0.56 ( -1.81 – 0.69)0.3434-2.80 (-3.12 to -2.48) < 0.0000012002 – 2010-1.69 ( -2.02 – -1.35) < 0.0000012010 – 2015-3.11 ( -3.91 – -2.30)0.0000042015 – 2020-5.20 ( -6.03 – -4.36) < 0.0000012020 – 2023-3.41 ( -4.83 – -1.96)0.000325South1999 – 2005-0.93 ( -1.41 – -0.45)0.001001-2.66 (-2.92 to -2.40) < 0.0000012005 – 2013-2.45 ( -2.82 – -2.08) < 0.0000012013 – 2019-4.39 ( -5.01 – -3.77) < 0.0000012019 – 2023-3.03 ( -3.95 – -2.10)0.000007West1999 – 2009-2.14 ( -2.40 – -1.88) < 0.000001-3.21 (-3.57 to -2.84) < 0.0000012009 – 2015-3.76 ( -4.49 – -3.02) < 0.0000012015 – 2019-5.44 ( -7.11 – -3.75)0.0000092019 – 2023-2.76 ( -3.89 – -1.62)0.000145Urban–ruralMetropolitan1999 – 2001-0.36 ( -1.40 – 0.70)0.456499-2.83 (-2.99 to -2.66) < 0.0000012001 – 2005-1.53 ( -2.04 – -1.02)0.0001312005 – 2010-2.24 ( -2.56 – -1.91) < 0.0000012010 – 2014-3.08 ( -3.59 – -2.57)0.0000012014 – 2020-4.79 ( -4.97 – -4.61) < 0.000001Nonmetropolitan1999 – 20011.40 ( -0.68 – 3.52)0.167806-1.73 (-1.97 to -1.48) < 0.0000012001 – 2008-0.78 ( -1.12 – -0.44)0.0003622008 – 2014-1.86 ( -2.31 – -1.42)0.0000022014 – 2020-3.70 ( -4.04 – -3.35) < 0.000001 Annual Percentage Changes (APCs) and Average Annual Percentage Changes (AAPCs) in Bronchus and Lung Cancer-related mortality in the United States from 1999 to 2023 The AAMR per 100,000 adults of Bronchus and lung cancer, stratified by sex in the United States between 1999 and 2023. AAMR, age-adjusted mortality rate; APC, annual percent change;;*, APC was found to be statistically significant at α < 0.05 Stratification by age group Throughout the study period, the crude mortality rates (CMRs) were highest among adults aged ≥ 85 years, falling from 296.85 in 1999 to 275.79 in 2023 (AAPC: -0.55, 95% CI: -0.86 to -0.24) (Supplementary Fig. 1). Marked reductions were also observed in adults aged 75–84 years (361.89 to 225.96, AAPC: -2.02, 95% CI: -2.24 to -1.79), with the steepest decline occurring between 2012 and 2023 (APC: -3.78; 95% CI: -4.01 to -3.55). A sustained downward trajectory was documented for the 65–74 age group (281.29 to 128.58, AAPC: -3.238, 95% CI: -3.51 to -2.96). Successively younger cohorts exhibited progressively sharper decreases, 55–64, 45–54, and 35–44 years—each with AAPC values of -3.277, -4.50, and -5.16, respectively (all P < 0.05). The 25–34 age group maintained the lowest CMRs throughout, remaining below 0.5 per 100 000 and decreasing modestly (AAPC: -2.515, 95% CI: -3.07 to -1.96) (Supplementary Fig. 1, Table 1). Stratification by sex In the sex-stratified analysis, age-adjusted mortality rates (AAMR) remained consistently higher among males than females from 1999 to 2023(Supplementary Table 2); however, the decline was markedly steeper in males (AAPC: males -3.35; 95% CI -3.68 to -3.01; females -1.85; 95% CI: -2.09 to -1.61). The sharpest decrease for males occurred between 2015 and 2018 (APC -5.62; 95% CI: -7.72 to -3.47). While female AAMR also exhibited a sustained and significant downward trend, albeit with a gentler slope (Table 2, Supplementary Table 2, Fig. 1). Stratification by race/ethnicity When stratified by race/ethnicity, age-adjusted mortality rates (AAMRs) in 1999 showed a clear gradient: non-Hispanic Black (NH Black) had the highest burden at 101.50 (95%CI: 99.91 to 103.10), followed by non-Hispanic White (NH White) at 88.43 (95%CI: 87.95 to 88.92), non-Hispanic Other (NH Other) at 45.79 (95%CI: 43.87 to 7.70), and Hispanic or Latino at the lowest level, 38.68(95%CI: 37.35 to 40.01) (Table 2, Supplementary Table 3). Notably, NH Black experienced the sharpest decline in AAMR over the study period, with an average annual percentage change of -3.05 (95% CI: -3.26 to -2.83). The steepest reduction occurred between 2013 and 2020, reaching an annual percentage change of -4.95 (95% CI: -5.33 to -4.57). Consequently, the NH Black AAMR first fell below that of NH White in 2015 and has remained lower ever since, while the NH White rate has stayed above all other racial/ethnic groups. In contrast, Hispanic or Latino and NH Other groups experienced more gradual declines, yet their AAMRs have consistently remained below those of the other two groups (Supplementary Fig. 2). Stratification by census region Across all census regions, age-adjusted mortality rates (AAMRs) declined steadily and significantly throughout the study period. (Supplementary Table 4) The South and Midwest maintained comparatively high levels, with nearly identical rates and trajectories (average annual percentage changes (AAPCs): -2.66%; 95% CI: -2.92 to -2.40 versus -2.80%; 95% CI: -3.12 to -2.48, respectively). By contrast, the West consistently recorded the lowest AAMR and exhibited the steepest decline nationwide (AAPC -3.21%; 95% CI: -3.57 to -2.84) (Supplementary Fig. 3). Stratification by urban–rural Overall, age-adjusted mortality rates (AAMRs) declined in both metropolitan and non-metropolitan areas throughout the study period, with metropolitan areas experienced the sharper decrease (Table 2, Supplementary Table 5). From 1999 to 2020, AAMRs in metropolitan fell steadily, registering an overall average annual percentage change (AAPC) of -2.83 (95% CI: -2.99 to -2.66); the most pronounced drop occurred between 2014 and 2020 (APC: -4.79%; 95% CI: -4.97 to -4.61) (Supplementary Table 5, Fig. 4). In non-metropolitan areas, AAMRs likewise trended downward, interrupted only by modest upticks in 2000 and 2007, and the overall decline was more gradual compared with metropolitan (AAPC: -1.73; 95% CI: -1.97 to -1.48) (Supplementary Fig. 4). Stratification by state Across all states, the age-adjusted mortality rate (AAMR) for bronchus and lung cancer showed a consistent decline from 1999 to 2023(Supplementary Table 6). The percent change of AAMR values were all negative, ranging from -32% to -59% (Supplementary Table 6), indicating a reduction in mortality rates over the 25-year period. The District of Columbia exhibited the largest reduction in mortality rates, with a percent change of -59%. Nevada and California followed closely, with percent changes of -57% and -56%, respectively. In 1999, the highest AAMR was observed in Mississippi (108.93 per 100,000), while the lowest was in Utah (40.87 per 100,000). By 2023, the highest AAMR was in Kentucky (75.62 per 100,000), and the lowest remained in Utah (23.76 per 100,000) (Supplementary Table 6). The overall reduction in AAMRs was substantial, with many states experiencing a more than 50% decrease in mortality rates. Despite the general downward trend, there was significant variability in the magnitude of the decline among different states. States such as Kentucky, West Virginia, and Louisiana still had relatively high AAMRs in 2023, although they also showed notable reductions compared to 1999. In contrast, states like Utah, Colorado, and Washington exhibited lower initial AAMRs in 1999 and maintained lower levels in 2023 (Fig. 2, Supplementary Table 6). Figure A, The AAMR per 100,000 of Bronchus and lung cancer of the District of Columbia, all 50 states in the United States between 1999 and 2020. Figure B, The AAMR per 100,000 EC of the District of Columbia, all 50 states in the United States between 2018 and 2023. AAMR, age-adjusted mortality rate; APC, annual percent change; (In the CDC WONDER database, the data for each state was segmented into 1999–2020 and 2018–2023 during data extraction, making it unable to obtain the overall AAMR for 1999–2023. Therefore, the AAMRs for these two periods is presented separately.) Discussion The 4.7% annual decline during 2014–2019 coincided with state Medicaid expansion (2014) and FDA approval of Osimertinib (2015), suggesting that insurance gains and targeted therapy probably amplified the downturn; cohort studies with smoking histories are needed to estimate their relative contributions [23, 24]. However, several notable disparities and trends found in this study warrant further investigation and targeted interventions. The analysis of Bronchus and Lung Cancer mortality rates across different age groups from 1999 to 2023 reveals significant trends and patterns that provide valuable insights into the disease dynamics over time. The data show a consistent decline in crude mortality rates across most age groups, indicating improvements in healthcare, early detection, and treatment options for Bronchus and Lung Cancer [25, 26]. Age is an established determinant of lung-cancer mortality; the steeper AAPC in progressively younger cohorts indicates that early-detection programs, smoking-cessation policies and novel therapies may be exerting disproportionate benefit among the non-elderly. Understanding these age-specific trajectories helps prioritize resource allocation [10]. Consistent with previous research, males exhibited higher AAMRs than females throughout the study period [10]. The 1.5-fold faster decline in males tracks the 2012–2018 CDC ‘Tips From Former Smokers’ campaign that disproportionately increased quit attempts among men; future campaigns should use female-targeted messaging and social-media channels to narrow the gap [23, 24]. Additionally, biological and physiological differences between sexes could also contribute to the observed disparities. For instance, men may have a higher susceptibility to the carcinogenic effects of tobacco smoke or other risk factors. While both sexes experienced significant declines in AAMRs over the years, the steeper decline in males parallels the timing of targeted smoking-cessation campaigns; however, without person-level smoking histories, we cannot establish a causal link [26, 27]. However, continued efforts are needed to address the remaining gap and ensure that both sexes benefit equally from public health initiatives. Consistent with national surveillance data, non-Hispanic (NH) Black individuals exhibited higher AAMRs than NH White individuals throughout the study period—a mortality excess that persists despite their historically lower smoking prevalence [25, 28]. This disparity likely reflects the compounded effects of targeted menthol cigarette marketing, residential segregation near industrial pollutants, and delayed access to guideline-concordant therapies and screening. future public health initiatives should prioritize culturally tailored cessation programs and community-based lung-cancer screening in underserved neighborhoods to narrow this gap. Conversely, Hispanic or Latino populations showed the lowest AAMRs, potentially reflecting protective smoking behaviors, favorable genetic variants in carcinogen metabolism, and stronger social support networks that facilitate tobacco cessation While all racial/ethnic groups experienced significant AAMR declines compatible with population-level tobacco-control policies, the persisting absolute gap suggests that uniform interventions are insufficient [29], without individual-level data on smoking intensity, occupational exposures, and treatment access, we cannot disentangle biological from socioeconomic drivers. Nevertheless, eliminating these disparities will require targeted policies that address structural barriers to care alongside continued broad-based prevention efforts [30]. The differences in AAMRs across census regions and urban–rural classifications highlight the importance of regional and local factors in lung cancer mortality. The Northeast region, which had higher initial AAMRs, experienced a significant decline over the study period, possibly due to early adoption of smoking cessation programs and better access to healthcare. In contrast, the Midwest and South regions, which had the highest AAMRs in the later years, may require more focused efforts to address the underlying causes of lung cancer mortality. The higher AAMRs in non-metropolitan areas compared to metropolitan areas could be attributed to several factors, including limited access to specialized healthcare, fewer smoking cessation resources, and potentially higher exposure to environmental carcinogens such as radon [31–33]. The 2.8% vs 1.7% annual decline suggests that mobile Low-Dose Computed Tomography (LDCT) units and state tobacco-tax differentials are working, but the 14% higher non-metro rate in 2020 signals access gaps; Medicare and Medicaid could equalize reimbursement for rural low-dose CT and incentivize teleradiology networks to close the deficit [34]. However, the continued higher rates in non-metropolitan areas suggest that targeted interventions are needed to address the unique challenges faced by these communities. For example, increasing the availability of smoking cessation programs and improving access to lung cancer screening in rural areas could help reduce the mortality gap [31, 35]. The substantial variability in AAMRs among different states highlights the importance of state-specific factors in lung cancer mortality. States such as Kentucky, West Virginia, and Arkansas, which had relatively high AAMRs in 2023, may benefit from targeted public health initiatives and policy changes to reduce smoking rates and improve access to healthcare. In contrast, states like Utah, Colorado, and New Mexico, which had lower initial AAMRs and maintained lower levels in 2023, may serve as models for other states to emulate. The large reductions in AAMRs observed in many states indicate the potential for further improvements through sustained efforts to address the risk factors and underlying causes of lung cancer [16]. State-level policies such as tobacco control measures, funding for cancer screening programs, and support for research into novel treatments could play a crucial role in reducing lung cancer mortality. The slight increase in AAMRs from 2020 to 2023 coincided with the COVID-19 pandemic; whether this reflects delayed care, increased smoking, or other pandemic-related factors requires dedicated investigation. Additionally, the stress and lifestyle changes associated with the pandemic may have led to increased smoking rates or other unhealthy behaviors that could have exacerbated the risk of lung cancer. Further research is needed to fully understand the impact of the COVID-19 pandemic on lung cancer mortality and to develop strategies to mitigate any long-term effects [36]. To close persistent gaps, the following policies could be implemented: (1) high-burden states raise tobacco tax to ≥ $2/pack and expand Medicaid cessation coverage [37]; (2) rural counties deploy mobile LDCT, tele-oncology and radon mitigation [38]; (3) minority communities use culturally tailored counseling plus cohort studies [39]; (4) younger adults receive vaping-cessation support and flavor-tobacco bans, all backed by state funds and annual mortality metrics for rapid course correction [37]. When individual-level data become accessible, a multilevel linear regression adjusting for smoking, education and radon levels—guided by a directed acyclic graph—should be fitted to quantify the independent contributions of race, rurality and region and to examine interactions such as rural region or race rurality. Conclusion This study on bronchus and lung cancer-related mortality in the United States from 1999 to 2023 revealed several key findings: There was a significant decrease in age-adjusted mortality rates (AAMRs) for bronchus and lung cancer across the United States, suggesting progress in reducing the population burden of this disease, although the absence of adjusted effect estimates precludes causal attribution. Stratification across different populations all showed AAMR disparities, underscoring the need for tailored public-health strategies for each group. Likewise, pronounced region- and urban–rural differences indicate that policy interventions must be devolved to the state and even county level. At the same time, we observed a slight AAMR rebound during 2020–2023 in multiple strata, probably related to the COVID-19 pandemic. Limitations and future research This study has several limitations inherent to its ecological design. First, the use of aggregate death-certificate data and underlying-cause ICD-10 codes may introduce misclassification bias; lung cancer is frequently underreported on death certificates when competing comorbidities (e.g., COPD or cardiovascular disease) are present. Second, the analysis was relied on population-level surveillance data, we cannot link temporal trends to individual-level smoking histories, pack-years, occupational exposures, or screening uptake—limiting causal inference regarding the drivers of observed disparities. Third, changes in racial/ethnic classification policies over the 1999–2023 study period may have modestly affected the accuracy of demographic categorization, potentially introducing temporal inconsistencies in how racial and ethnic groups were defined and recorded. Future research should aim to incorporate more detailed individual-level data to provide a more comprehensive understanding of the factors contributing to lung cancer mortality. Furthermore, studies should focus on identifying the specific mechanisms underlying the observed disparities and developing targeted interventions to address these disparities. Supplementary Information Additional file 1: Fig. 1 The crude mortality rate per 100,000 adults of Bronchus and lung cancer, stratified by age group in the United States between 1999 and 2023. APC, annual percent change; *, APC was found to be statistically significant at α < 0.05 Additional file 2: Fig. 2 The AAMR per 100,000 adults of Bronchus and lung cancer stratified by race/ethnicity in the United States between 1999 and 2023. AAMR, age-adjusted mortality rate; APC, annual percent change; *, APC was found to be statistically significant at α < 0.05 Additional file 3: Fig. 3 The AAMR per 100,000 adults of Bronchus and lung cancer, stratified by census region in the United States between 1999 and 2023. AAMR, age-adjusted mortality rate; APC, annual percent change; *, APC was found to be statistically significant at α < 0.05 Additional file 4: Fig. 4 The AAMR per 100,000 adults of Bronchus and lung cancer, stratified by urban-rural in the United States between 1999 and 2023. AAMR, age-adjusted mortality rate; APC, annual percent change; *, APC was found to be statistically significant at α < 0.05 Additional file 5. Additional file 6. Additional file 7. Additional file 8. Additional file 9. Additional file 10. Author contributions Conception and design: Mingfeng Wei, Huibiao Zhang, Xiaoyong Shen; administrative support: Mingfeng Wei, Xiaoyu Chen, Wei Cheng, Xuelin Zhang; database acquisition and cleaning: Mingfeng Wei, Xiaoyu Chen, Wei Cheng, Lefei Hu, Shixiang Guo; data analysis and interpretation: Mingfeng Wei, Xiaoyu Chen, Wei Cheng, Zheng Li, Huibiao Zhang, Xiaoyong Shen; manuscript writing: all authors; final approval of manuscript: all authors. Funding National Natural Science Foundation of China (Grant No. 82372611). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Mingfeng Wei, Yun Wu and Zheng Li contributed equally to this work as co-first authors. Xunxia Zhu and Xiaoyong Shen contributed equally to this work. References Associated Data Supplementary Materials Additional file 1: Fig. 1 The crude mortality rate per 100,000 adults of Bronchus and lung cancer, stratified by age group in the United States between 1999 and 2023. APC, annual percent change; *, APC was found to be statistically significant at α < 0.05 Additional file 2: Fig. 2 The AAMR per 100,000 adults of Bronchus and lung cancer stratified by race/ethnicity in the United States between 1999 and 2023. AAMR, age-adjusted mortality rate; APC, annual percent change; *, APC was found to be statistically significant at α < 0.05 Additional file 3: Fig. 3 The AAMR per 100,000 adults of Bronchus and lung cancer, stratified by census region in the United States between 1999 and 2023. AAMR, age-adjusted mortality rate; APC, annual percent change; *, APC was found to be statistically significant at α < 0.05 Additional file 4: Fig. 4 The AAMR per 100,000 adults of Bronchus and lung cancer, stratified by urban-rural in the United States between 1999 and 2023. AAMR, age-adjusted mortality rate; APC, annual percent change; *, APC was found to be statistically significant at α < 0.05 Additional file 5. Additional file 6. Additional file 7. Additional file 8. Additional file 9. Additional file 10. Data Availability Statement No datasets were generated or analysed during the current study.